Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma SubgroupsStefan G. van Ravensteijn, Ingrid M.E. Desar, Yvonne M.H. Versleijen‐Jonkers et al.|Cancers|2022Cited by 19
Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Yvonne M.H. Versleijen‐Jonkers et al.|Clinical Cancer Research|2025Cited by 6
Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk DiseaseKalijn F. Bol, Inge Marie Svane|Investigative Ophthalmology & Visual Science|2025Cited by 1
Supplementary Figure 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Jacco J. de Haan et al.|Unknown|2025Cited by 0
Supplementary Figure 2 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Jacco J. de Haan et al.|Unknown|2025Cited by 0